Oncolytic Probiotics Mediated Breast Cancer Treatment

Breast cancer is a heterogeneous disease with two most common types of breast cancer, ductal and lobular carcinoma, ductal being by far the most common. The development of targeted drug delivery shows the great promise to overcome the hurdles of conventional drug therapy approach in breast cancer treatment. Conjugation of nanocarriers with targeting ligands is a potential therapeutic approach to treat cancer diseases.

Gut Microbiome Analysis

Fig.1 monoclonal antibodies and small-molecule inhibitors for breast cancer

Breast cancer targeted drugs obstruct the growth of cancer through interfering with the function of specific molecules that are responsible for cancer cell proliferation, survival, migration, invasion, metastasis, apoptosis, cell-cycle progression, angiogenesis and other vital cell cycle pathways. With the latest developments in molecular biology and immunotherapy, tailoring personalized therapies have been tailored to the specific pathophysiology of different types of breast cancers. Targeted therapy drugs which are generally available for breast cancer are listed below.

Target Types Agent Manufacturer Start Marketing Date
HER2 ADC Kadcyla Roche 2013
mTOR Small molecule Certican Afinitor Zortress Novartis 2009
EGFR, HER2 Small molecule Tykerb GSK 2007
CDK4/6 Small molecule Ibrance Pfizer 2015
HER2 mAb Perjeta RocheV 2012
HER2 mAb Herceptin Roche 1998
CDK4/6 Small molecule Verzenio Lilly 2017
CDK4/6 Small molecule Kisqall Novartis 2017
EGFR, HER2, HER4 Small molecule Nerlynx  2017
EGFR, HER2 Small molecule airuini Hengrui 2018
PARP Small molecule Talzenna Pfizer 2018
PARP Small molecule Lynparza AstraZeneca 2018

In the field of cancer treatment, it was observed that the bacteria have the ability to deliver tumor-specific anticancer genes and the potential tumor-targeting antitumor capability. As a leader in oncolytic bacteria genome editing, Creative Biogene provides a "one-stop shop" tailored to your gene research needs. We have expertise in gene knockout, knock-in/replacement and site-directed mutagenesis. Creative Biogene is able to provide you the comprehensive oncolytic bacteria genome editing service, including traditional recombineering system, CRISPR/Cas 9 system and site-specific recombination system.

The ideal criteria for the selection of therapeutic bacteria are as follows:

• non-toxic to the host
• selective for a specific type of tumor
• non-immunogenic
• harmless to normal tissue
• manipulated easily
• controlled

Creative Biogene is dedicated to providing Complete Solutions for oncolytic bacteria genome editing to help you every step of the way in your genome editing workflow. And we offer full-service for genetic modification which has been successfully achieved in microorganisms, such as E. coli, SalmonellaStreptomyces, Clostridium, Bacillus subtilisSaccharomyces cerevisiae, filamentous fungi, and so on. Simply let us know how you want the genome to be edited. We will propose the best strategy for you.

References
1. Munagala, R., Aqil, F., & Gupta, R. C. (2011). Promising molecular targeted therapies in breast cancer. Indian journal of pharmacology, 43(3), 236–245.
2. Gomhor J. Alqaraghulia, Hasanain & Kashanian, Soheila & Rafipour, Ronak. (2019). A Review on Targeting Nanoparticles for Breast Cancer. Current pharmaceutical biotechnology. 20.
3. Masoud, V., & Pagès, G. (2017). Targeted therapies in breast cancer: New challenges to fight against resistance. World journal of clinical oncology, 8(2), 120–134.

For research use only.

Quick Inquiry

  • Verification code

Creative Biogene is fully engaged in developing unique technologies that provide global scientists with high quality products and satisfactory services to facilitate the investigation of microbial researches.

Subscribe

Enter your email address to subscribe.

Microbial Fermentation

• Microbial Fermentation Service

Copyright © Creative Biogene. All Rights Reserved.